Disc Medicine Announces Pricing of $225.5 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants

Core Viewpoint - Disc Medicine, Inc. has announced an upsized underwritten offering of common stock and pre-funded warrants, aiming to raise approximately $225.5 million to fund research and clinical development of its product candidates and for general corporate purposes [1][2]. Group 1: Offering Details - Disc is selling 3,918,182 shares of common stock at an offering price of$55.00 per share and pre-funded warrants to purchase 181,818 shares at $54.9999 each [1]. - The total gross proceeds from the offering are expected to be around$225.5 million, before deducting underwriting discounts and commissions [1]. - Underwriters have a 30-day option to purchase up to an additional $33.825 million of shares at the public offering price [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be used to fund research and clinical development of current or additional product candidates, support commercialization of bitopertin for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and for working capital and other general corporate purposes [2]. Group 3: Underwriters - Jefferies, Leerink Partners, Stifel, and Cantor are acting as joint book-running managers for the offering, while BMO Capital Markets, LifeSci Capital, Wedbush PacGrow, and H.C. Wainwright & Co. are co-managers [3]. Group 4: Company Overview - Disc Medicine is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel treatments for serious hematologic diseases, targeting fundamental biological pathways of red blood cell biology [6].